As pharma companies use more third parties, risk management must maintain compliance, quality, and reputation without slowing growth.
In this article, originally published Feb. 4, 2025, in Life Science Leader, Crowe specialists identify what’s involved in building effective third-party risk management programs.
Managing third-party risk is one of the most arduous challenges facing pharmaceutical companies, and regulatory requirements are just one piece of this puzzle.
Pharmaceutical organizations are continually evolving – rapidly. Often, this evolution involves an increased use of third parties. As changes occur, companies’ third-party risk management (TPRM) programs must continue to adapt to ensure compliance, maintain quality, and ultimately help protect the companies’ reputation. The challenge is doing so effectively without compromising growth or exposing organizations to unnecessary risk.
Manage third-party risk in health and sciences
We can help you identify and address increasing complexity in third-party risk. Learn more about how our specialized knowledge and experience can help.
Life sciences IPO readiness begins before filing, and an IPO readiness assessment helps reduce delays, strengthen governance, and boost preparedness.
Public market investors evaluate financial discipline, governance, and execution as indicators of life sciences IPO readiness and long-term growth.
Learn the five pillars of life sciences IPO readiness for public market success, from strategy and science to operations, finance, and governance.
Life sciences IPO readiness begins before filing, and an IPO readiness assessment helps reduce delays, strengthen governance, and boost preparedness.
Public market investors evaluate financial discipline, governance, and execution as indicators of life sciences IPO readiness and long-term growth.
Learn the five pillars of life sciences IPO readiness for public market success, from strategy and science to operations, finance, and governance.